Scinai Immunotherapeutics Statistics
Total Valuation
SCNI has a market cap or net worth of $3.68 million. The enterprise value is $7.98 million.
| Market Cap | 3.68M |
| Enterprise Value | 7.98M |
Important Dates
The next estimated earnings date is Friday, August 9, 2024, before market open.
| Earnings Date | Aug 9, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
SCNI has 838,578 shares outstanding. The number of shares has increased by 56.43% in one year.
| Shares Outstanding | 838,578 |
| Shares Change (YoY) | +56.43% |
| Shares Change (QoQ) | +29.66% |
| Owned by Insiders (%) | 18.54% |
| Owned by Institutions (%) | 7.05% |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.73
| Current Ratio | 2.73 |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -107.90% |
| Return on Capital (ROIC) | -54.46% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$635,419 |
| Employee Count | 31 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -69.93% in the last 52 weeks. The beta is 2.45, so SCNI's price volatility has been higher than the market average.
| Beta (5Y) | 2.45 |
| 52-Week Price Change | -69.93% |
| 50-Day Moving Average | 3.76 |
| 200-Day Moving Average | 5.27 |
| Relative Strength Index (RSI) | 55.05 |
| Average Volume (20 Days) | 1,595,969 |
Short Selling Information
| Short Interest | 20,646 |
| Short Previous Month | 13,736 |
| Short % of Shares Out | 2.46% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.12 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -2.32M |
| Pretax Income | -5.40M |
| Net Income | -19.70M |
| EBITDA | -5.26M |
| EBIT | -5.40M |
| Earnings Per Share (EPS) | -$13.17 |
Balance Sheet
The company has $1.36 million in cash and $5.66 million in debt, giving a net cash position of -$4.30 million or -$5.12 per share.
| Cash & Cash Equivalents | 1.36M |
| Total Debt | 5.66M |
| Net Cash | -4.30M |
| Net Cash Per Share | -$5.12 |
| Equity (Book Value) | -1.40M |
| Book Value Per Share | -1.67 |
| Working Capital | 913,231 |
Cash Flow
In the last 12 months, operating cash flow was -$2.14 million and capital expenditures -$173,648, giving a free cash flow of -$2.31 million.
| Operating Cash Flow | -2.14M |
| Capital Expenditures | -173,648 |
| Free Cash Flow | -2.31M |
| FCF Per Share | -$4.56 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SCNI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -56.43% |
| Shareholder Yield | -56.43% |
| Earnings Yield | -535.07% |
| FCF Yield | -62.74% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on May 21, 2024. It was a reverse split with a ratio of 1:10.
| Last Split Date | May 21, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |